





























1	-
	5
-	

		SCREENING METHODS
Screening Method	Frequency	Considerations
Colonoscopy	Every 10 years	Screening and diagnostic
Flexible sigmoidoscopy	Every 5 years	
CT colonography	Every 5 years	Insufficient evidence about harms of extracolonic findings
Flexible sigmoidoscopy + FIT	Every 10 years + yearly	
FIT	Yearly	Can be done with single specimen
FIT-DNA	Every 1 or 3 years	Specificity is lower than for FIT, but improved sensitivity







		NCER
Women aged 50 to 74 years	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.	В
Women aged 40 to 49 years	The decision to start screening mammography in women prior to age 50 years should be an individual one. Women who place a higher value on the potential benefit than the potential harms may choose to begin biennial screening between the ages of 40 and 49 years.	C

COMPARISON NCCN USPSTF ACR Age to start mammograms 50 40 40 40 45 Life expectancy <10 years Age to stop mammograms As long as in good health Life expectancy <5-7 years 74 Not established Annual 45-54; Annual every 1-2 years 55+ Interval Every 2 years Annual Annual

21





	PROSTATE CANCER	
Men ages 55 to 69 years	The USPSTF recommends that clinicians inform men ages 55 to 69 years about the potential benefits and harms of prostate-specific antigen (PSA)- based screening for prostate cancer. The decision about whether to be screened for prostate cancer should be an individual one. Screening offers a small potential benefit of reducing the chance of dying of prostate cancer. However, many men will experience potential harms of screening, including false-positive results that require additional testing and possible prostate biogsview ceredity and the user of the user of the screening offers and overtreatment; and treatment complications, such as incontinence and impotence. The USPSTF neormends individualized decisionmaking about screening for prostate cancer after discussion with a clinician, so that each man has an oportunity to understand the potential benefits and harms of screening and to incorporate his values and preferences into his decision. Please refers to the Clinical Considerations screening in African American men and men with a family history of prostate cancer for more information on these higher-tak populations.	C

RATIONALE





	Number of Men	
Men invited to screening	1,000	
Men who receive at least 1 positive PSA test result	240	
Men who have 1 or more transrectal prostate biopsies	220†	
Men hospitalized for a biopsy complication	2	
Men diagnosed with prostate cancer	100	
Men who initially receive active treatment with radical prostatectomy or radiation therapy	65	
Men who initially receive active surveillance	30	
Men who initially receive active surveillance who go on to receive active treatment with radical prostatectomy or radiation therapy	15	
Men with sexual dysfunction who received initial or deferred treatment	60	
Men with urinary incontinence who received initial or deferred treatment	15	
Men who avoid metastatic prostate cancer	3	
Men who die of causes other than prostate cancer	200	
Men who die of prostate cancer despite screening, diagnosis, and treatment	5	
Men who avoid dving of prostate cancer	1 to 2	









Adults aged 40 to 59 years with a 10% or greater 10-year cardiovascular disease (CVD) risk	The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit.	C
Adults 60 years or older	The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults 60 years or older.	D

COMPARISON

ACC/AHA

Select 40-70yo with high CVD risk who are not at increased bleeding risk

ADA

Men >50yo and women >60yo with DMT1 or DMT2 with 10-year CVD risk of >10%

33



































